Journal
LUNG CANCER
Volume 53, Issue 3, Pages 295-302Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2006.05.022
Keywords
chromium; carcinogenesis; lung cancer; p16 gene; methylation; protein expression
Categories
Ask authors/readers for more resources
Study objectives: It is known that chromium is one of the important inhaled carcinogens that cause lung cancer. Our previous studies revealed a variety of genetic changes in lung cancers from chromate-exposed workers (chromate lung cancer). However, the epigenetic effects of chromium are not understood. Materials and methods: We investigated the methylation of the p16 gene using a methylation-specific PCR method in 30 chromate lung cancers and 38 non-chromate lung cancers, and the expression of the p16 protein using immunohistochemistry in 25 chromate lung cancers. Results: Ten (33%) chromate Lung cancers showed methylation of the p16 promoter region. On the other hand, 10 (26%) of the non-chromate lung cancers also showed it. The frequency of p16 methylation in non-chromate lung cancer was 0%, 33% and 30% for low (<= 600), moderate (<600, >1000) and high (>= 1000) Brinkman indexes, respectively. However, the frequency of p16 methylation in chromate lung cancer was constant, irrespective of the Brinkman index. In chromate lung cancer, patients with chromate exposure of less than 15 years never had p16 methylation, while 40% (>= 25 years) or 43% (>= 15, <25 years) of patients with chromate exposure of more than 15 years did. In chromate lung cancer, chromate exposure, not smoking, mainly influenced the p16 methylation. Most of the chromate lung cancers with p16 methylation (85.7%) showed repression of the p16 protein. Conclusions: We speculate that not only genetic but also epigenetic alterations are involved in the carcinogenesis due to chromium. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available